Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2.
Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.
Engelhardt
M
M
Medizinische Klinik I, University of Freiburg, Germany.
Rump
J A
JA
Hellerich
U
U
Mertelsmann
R
R
Lindemann
A
A
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000209:etiology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology
D000305:Adrenal Cortex Hormones; D007376:Interleukin-2